RESUMO
Marked elevation in the brain concentration of N-acetyl-L-aspartate (NAA) is a characteristic feature of Canavan disease, a vacuolar leukodystrophy resulting from deficiency of the oligodendroglial NAA-cleaving enzyme aspartoacylase. We now demonstrate that inhibiting NAA synthesis by intracisternal administration of a locked nucleic acid antisense oligonucleotide to young-adult aspartoacylase-deficient mice reverses their pre-existing ataxia and diminishes cerebellar and thalamic vacuolation and Purkinje cell dendritic atrophy. Ann Neurol 2020;87:480-485.
Assuntos
Ácido Aspártico/análogos & derivados , Doença de Canavan/tratamento farmacológico , Oligonucleotídeos Antissenso/uso terapêutico , Acetiltransferases/antagonistas & inibidores , Amidoidrolases/deficiência , Amidoidrolases/genética , Animais , Ácido Aspártico/biossíntese , Ataxia/complicações , Ataxia/tratamento farmacológico , Atrofia/complicações , Atrofia/tratamento farmacológico , Doença de Canavan/complicações , Doença de Canavan/patologia , Cerebelo/patologia , Feminino , Técnicas de Silenciamento de Genes , Infusões Intraventriculares , Masculino , Camundongos , Mutação , Oligonucleotídeos Antissenso/administração & dosagem , Células de Purkinje/patologia , Teste de Desempenho do Rota-Rod , Tálamo/patologia , Vacúolos/efeitos dos fármacos , Vacúolos/patologiaRESUMO
Canavan disease is a fatal neurological disorder caused by defects in the gene that produces the enzyme aspartoacylase. Enzyme replacement therapy can potentially be used to overcome these defects if a stable enzyme form that can gain access to the appropriate neural cells can be produced. Achieving the proper cellular targeting requires a modified form of aspartoacylase that can traverse the blood-brain barrier. A PEGylated form of aspartoacylase that shows dramatic enhancement in brain tissue access and distribution has been produced. While the mechanism of transport has not yet been established, this modified enzyme is significantly less immunogenic than unmodified aspartoacylase. These improved properties set the stage for more extensive enzyme replacement trials as a possible treatment strategy.
Assuntos
Amidoidrolases/farmacocinética , Encéfalo/metabolismo , Polietilenoglicóis/farmacocinética , Amidoidrolases/imunologia , Animais , Barreira Hematoencefálica/metabolismo , Doença de Canavan/tratamento farmacológico , Avaliação Pré-Clínica de Medicamentos , Terapia de Reposição de Enzimas , Humanos , Masculino , Ratos Sprague-Dawley , Distribuição TecidualRESUMO
Canavan disease (CD) is a fatal dysmyelinating genetic disorder associated with aspartoacylase deficiency, resulting in decreased brain acetate levels and reduced myelin lipid synthesis in the developing brain. Here we tested tolerability of a potent acetate precursor, glyceryl triacetate (GTA), at low doses in two infants diagnosed with CD, aged 8 and 13 months. Much higher doses of GTA were evaluated for toxicity in the tremor rat model of CD. GTA was given orally to the infants for up to 4.5 and 6 months, starting at 25 mg/kg twice daily, doubling the dose weekly until a maximum of 250 mg/kg reached. Wild-type and tremor rat pups were given GTA orally twice daily, initially at a dose of 4.2 g/kg from postnatal days 7 through 14, and at 5.8 g/kg from day 15 through 23, and thereafter in food (7.5%) and water (5%). At the end of the trial (approximately 90 to 120 days) sera and tissues from rats were analysed for changes in blood chemistry and histopathology. GTA treatment caused no detectable toxicity and the patients showed no deterioration in clinical status. In the high-dose animal studies, no significant differences in the mean blood chemistry values occurred between treated and untreated groups, and no lesions indicating toxicity were detectable in any of the tissues examined. Lack of GTA toxicity in two CD patients in low-dose trials, as well as in high-dose animal studies, suggests that higher, effective dose studies in human CD patients are warranted.
Assuntos
Doença de Canavan/tratamento farmacológico , Ratos , Tremor/tratamento farmacológico , Triacetina/administração & dosagem , Triacetina/efeitos adversos , Acetatos/administração & dosagem , Acetatos/efeitos adversos , Acetatos/química , Administração Oral , Animais , Animais Recém-Nascidos , Suplementos Nutricionais , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Feminino , Humanos , Lactente , Masculino , Ratos Endogâmicos WKY , Tremor/patologia , Triglicerídeos/químicaRESUMO
Canavan disease (CD) is a fatal genetic neurodegenerative disorder caused by mutations in the gene for aspartoacylase, an enzyme that hydrolyzes N-acetylaspartate (NAA) into L-aspartate and acetate. Because aspartoacylase is localized in oligodendrocytes, and NAA-derived acetate is incorporated into myelin lipids, we hypothesize that an acetate deficiency in oligodendrocytes is responsible for the pathology in CD, and we propose acetate supplementation as a possible therapy. In our preclinical efforts toward this goal, we studied the effectiveness of orally administered glyceryl triacetate (GTA) and calcium acetate for increasing acetate levels in the murine brain. The concentrations of brain acetate and NAA were determined simultaneously after intragastric administration of GTA. We found that the acetate levels in brain were increased in a dose- and time-dependent manner, with a 17-fold increase observed at 1 to 2 h in 20- to 21-day-old mice at a dose of 5.8 g/kg GTA. NAA levels in the brain were not significantly increased under these conditions. Studies using mice at varying stages of development showed that the dose of GTA required to maintain similarly elevated acetate levels in the brain increased with age. Also, GTA was significantly more effective as an acetate source than calcium acetate. Chronic administration of GTA up to 25 days of age did not result in any overt pathology in the mice. Based on these results and the current Food and Drug Administration-approved use of GTA as a food additive, we propose that it is a potential candidate for use in acetate supplementation therapy for CD.
Assuntos
Acetatos/uso terapêutico , Ácido Aspártico/análogos & derivados , Encéfalo/metabolismo , Doença de Canavan/tratamento farmacológico , Acetatos/análise , Animais , Ácido Aspártico/análise , Compostos de Cálcio , Doença de Canavan/metabolismo , Fígado/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BLRESUMO
Canavan disease is a devastating neurodegenerative childhood disease caused by mutations in aspartoacylase, an enzyme that deacetylates N-acetylaspartate to generate free acetate in the brain. Localization of aspartoacylase in different cell types in the rat brain was examined in an attempt to understand the pathogenesis of Canavan disease. In situ hybridization histochemistry with a riboprobe based on murine aspartoacylase cDNA was used in this study. The hybridization signal was detectable primarily in the myelin-synthesizing cells, namely oligodendroglia. These findings provide strong additional support for insufficient myelin synthesis as the pathogenic basis of Canavan disease and make a compelling case for acetate supplementation as a simple and noninvasive therapy for this fatal disease with no treatment.